ACE-031: Evidence-Based Review: Clinical Data and Practical Applications

ACE-031, also known as Ramatercept, is a synthetic protein that was developed as a potential treatment for Duchenne muscular dystrophy (DMD). It is a fusion protein that acts as a decoy receptor for myostatin and other related proteins, effectively inhibiting their muscle-growth-limiting effects. While the clinical development of ACE-031 was halted due to safety concerns, it remains a topic of interest in the research and bodybuilding communities for its potent muscle-building properties. This article provides an evidence-based review of ACE-031, including its mechanism of action, clinical trial data, and the reasons for its discontinuation.

Mechanism of Action: A Decoy Receptor

ACE-031 is a recombinant fusion protein that consists of the extracellular domain of the human activin receptor type IIB (ActRIIB) linked to a portion of a human antibody. This design allows it to circulate in the bloodstream and bind to proteins that normally signal through the ActRIIB receptor, such as myostatin and activin A. By acting as a decoy receptor, ACE-031 prevents these proteins from binding to their natural receptors on muscle cells, thereby inhibiting their negative regulatory effects on muscle growth. This leads to an increase in muscle mass and strength [1].

Clinical Trials and Efficacy

ACE-031 underwent several clinical trials to evaluate its safety and efficacy, primarily in patients with Duchenne muscular dystrophy.

• Phase 1 Studies: In a single ascending-dose study in healthy postmenopausal women, ACE-031 was found to be generally well-tolerated and resulted in a dose-dependent increase in lean body mass and muscle volume [2].
• Phase 2 Studies in DMD: A phase 2 study was initiated to evaluate the effects of ACE-031 in boys with DMD. The study showed trends toward increased lean mass and bone mineral density, as well as a reduction in fat mass. However, the trial was terminated early due to safety concerns [3].

Discontinuation and Safety Concerns

In 2011, the clinical development of ACE-031 was halted due to the emergence of adverse events in the phase 2 DMD trial. The specific safety concerns that led to the discontinuation were minor nosebleeds, gum bleeding, and small dilated blood vessels in the skin (telangiectasias). While these events were not considered life-threatening, they raised concerns about the long-term safety of the drug, particularly in a pediatric population [4]. The development of ACE-031 was officially discontinued in 2013.

Practical Applications and Black Market Use

Despite its discontinuation for clinical use, ACE-031 has found its way onto the black market, where it is sold as a performance-enhancing drug. Bodybuilders and athletes are drawn to its potent muscle-building effects. However, the use of black market ACE-031 is fraught with risks. The quality, purity, and dosage of these products are unregulated, and there is a lack of information on their long-term safety.

Parameter	Value
Administration	Subcutaneous injection
Clinical Trial Doses	1-3 mg/kg
Status	Discontinued

Key Takeaways

• ACE-031 is a decoy receptor for myostatin and other related proteins, designed to increase muscle mass and strength.

• Clinical trials showed promising effects on muscle growth but were halted due to safety concerns.

• The drug was associated with minor bleeding events and skin abnormalities.

• ACE-031 is not approved for human use and is sold on the black market, posing significant health risks.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.

References

[1] Cadena, S. M., D-Kates, J., van der Ploeg, L. H. T., & McPherron, A. C. (2010). ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in mice. PloS one, 5(10), e13335. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133335

[2] Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., & Kumar, R. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & nerve, 47(3), 416-423. https://pubmed.ncbi.nlm.nih.gov/23169607/

[3] Campbell, C., McMillan, H. J., Mah, J. K., Tarnopolsky, M., Selby, K., McClure, T., ... & D-Kates, J. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & nerve, 55(4), 458-464. https://pubmed.ncbi.nlm.nih.gov/27462804/

[4] Acceleron Pharma. (2013). Acceleron and Shire Announce Discontinuation of ACE-031 Development Program. Retrieved from https://www.businesswire.com/news/home/20130425005607/en/Acceleron-Shire-Announce-Discontinuation-ACE-031-Development